The Digital Lab Notebook for Life Sciences, Now Starting at Free

Life scientists currently spend more than 180 billion dollars every year to generate precious research results. Yet they don’t spend anywhere near as much effort on making the results of that research reproducible, searchable, and machine-readable. This results in needless waste and duplication; to paraphrase the famous saying, “Half the money we spend on research is repeated; the trouble is we don’t know which half.”

The classic solution has been the physical laboratory notebook. However, in an era of geographically distributed conglomerates, massive biomedical datasets, and increasingly computerized workflows, we will not attain reproducible research through good note-taking alone. We need modern tools.

That’s where Sajith Wickramasekara and Ashutosh Singhal of Benchling come in. They’ve built a suite of apps, centered around a digital laboratory notebook, that help life scientists design, run, record, and search the results of their very expensive experiments. Built by their team of fellow MIT engineers, Benchling’s technology has already been adopted by thousands of scientists across both industry and academia, and has a serious chance at becoming to biomedicine what GitHub has become to software engineering.

To understand the problem they are solving, it’s useful to review the state of data in the life sciences. Current systems separate each type of data scientists use into its own silo, making recreating the full context and results of an experiment impossible. The tools are poorly designed and don’t take advantage of the web, making sharing data difficult and wasting expensive researcher time on searching for old work or redoing known results. Imagine a software engineering team working without version control and you’ll have a sense of the status quo for most life science labs.

Benchling changes all that with a multipart offering for scientists that is, as of today, free for general use. The Benchling suite begins with single-purpose tools for cloning, gels, colony picking, primer design, and more. All of these different apps are connected to the scientist’s electronic lab notebook in the cloud. For the first time, the place where scientists do work is connected to where the work is recorded. Every action in Benchling is tracked, versioned, and can be retraced in the future. Instead of a paper notebook, scientists record observations and notes inline with the actual work they are doing, and can search across all of their lab’s current and historical information.

The result has been a crowd pleaser in the life sciences. Scientists love it because it’s well designed and unifies many disparate tools in one interface. Managers love it because they get visibility into what their scientists are doing. And executives love the sophisticated archival functionality as it helps organizations capture and preserve institutional knowledge such that when people leave the company, knowledge doesn’t leave with them.

With thousands of customers (including both academic labs and pharma companies) already on the Benchling platform, we believe their future is bright. That’s why I’m proud to announce that Andreessen Horowitz is leading a $5 million round of funding in Benchling to scale their operations. Our bet is simple: if a lab is spending a few million per year on generating precious life science data, they’ll now probably want to try Benchling out for free to make sure they don’t unnecessarily spend a few million more.

 

 

 

The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation.

This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments and certain publicly traded cryptocurrencies/ digital assets for which the issuer has not provided permission for a16z to disclose publicly) is available at https://a16z.com/investments/.

Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.